{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=69", "query": { "intervention": "Placebo once daily", "page": 69 }, "page_size": 10 }, "pagination": { "page": 69, "page_size": 10, "total_count": 5512, "total_pages": 552, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=70&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=68&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T18:10:04.677Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01389024", "title": "Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Stroke" ], "interventions": [ { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "54 Months", "sex": "ALL", "summary": "12 Months to 54 Months" }, "enrollment_count": 28, "start_date": "2012-08-16", "completion_date": "2022-05-24", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Kansas City, Missouri + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01389024" }, { "nct_id": "NCT03777059", "title": "12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Episodic Migraine" ], "interventions": [ { "name": "Atogepant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 910, "start_date": "2018-12-14", "completion_date": "2020-06-19", "has_results": true, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 138, "location_summary": "Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03777059" }, { "nct_id": "NCT05507203", "title": "ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "ABX464", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abivax S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 639, "start_date": "2022-11-16", "completion_date": "2025-06-25", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 54, "location_summary": "Dothan, Alabama • Guntersville, Alabama • Homewood, Alabama + 45 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05507203" }, { "nct_id": "NCT02092961", "title": "Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo of Fostamatinib", "type": "DRUG" }, { "name": "Placebo of Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 198, "start_date": "2011-02", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2014-06-25", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 6, "location_summary": "Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092961" }, { "nct_id": "NCT02059642", "title": "A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "ADHD", "Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type" ], "interventions": [ { "name": "MG01CI (1400 mg)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcobra Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 300, "start_date": "2014-03", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 18, "location_summary": "Gainesville, Florida • South Miami, Florida • Libertyville, Illinois + 15 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "Libertyville", "state": "Illinois" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059642" }, { "nct_id": "NCT06629259", "title": "Guanfacine for Alcohol Use Disorder (AUD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Guanfacine Extended Release (XR)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-10-03", "completion_date": "2029-09-07", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Newark, New Jersey", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06629259" }, { "nct_id": "NCT01705574", "title": "Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "E/C/F/TDF Placebo", "type": "DRUG" }, { "name": "ATV Placebo", "type": "DRUG" }, { "name": "RTV Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 583, "start_date": "2012-10-24", "completion_date": "2018-09-06", "has_results": true, "last_update_posted_date": "2019-09-20", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 41, "location_summary": "Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705574" }, { "nct_id": "NCT01387282", "title": "Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cachexia", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Anamorelin HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Helsinn Therapeutics (U.S.), Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 495, "start_date": "2011-07", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2017-10-27", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 14, "location_summary": "Corona, California • Fountain Valley, California • Glendale, California + 11 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387282" }, { "nct_id": "NCT00765882", "title": "Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Constipation" ], "interventions": [ { "name": "Linaclotide 290 micrograms", "type": "DRUG" }, { "name": "Linaclotide 145 micrograms", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 633, "start_date": "2008-09", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2013-01-30", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 100, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765882" }, { "nct_id": "NCT04614246", "title": "Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "BAY1817080", "type": "DRUG" }, { "name": "Elagolix", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 215, "start_date": "2021-01-29", "completion_date": "2022-05-03", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-03T18:10:04.677Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04614246" } ] }